For the quarter ended June 2025, Chemours (CC Quick QuoteCC - Free Report) reported revenue of $1.62 billion, up 5% over the same period last year. EPS came in at $0.58, compared to $0.38 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.57 billion, representing a surprise of +2.98%. The company delivered an EPS surprise of +26.09%, with the consensus EPS estimate being $0.46.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Other Segment: $15 million versus the four-analyst average estimate of $11.95 million. The reported number represents a year-over-year change of +15.4%.
• Revenues- Titanium Technologies: $657 million compared to the $646.02 million average estimate based on four analysts. The reported number represents a change of -2.4% year over year.
• Revenues- Advanced Performance Materials: $346 million versus $330.36 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
• Revenues- Thermal & Specialized Solutions: $597 million compared to the $579.52 million average estimate based on four analysts. The reported number represents a change of +16.4% year over year.
• Adjusted EBITDA- Titanium Technologies: $47 million compared to the $50 million average estimate based on four analysts.
• Adjusted EBITDA- Corporate and Other: $-53 million versus the four-analyst average estimate of $-59.68 million.
• Adjusted EBITDA- Other Segment: $4 million versus $1.93 million estimated by four analysts on average.
• Adjusted EBITDA- Advanced Performance Materials: $50 million compared to the $38.9 million average estimate based on four analysts.
• Adjusted EBITDA- Thermal & Specialized Solutions: $207 million versus $193.28 million estimated by four analysts on average.

View all Key Company Metrics for Chemours here>>>

Shares of Chemours have returned -1.7% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.